Critical Analysis: Catalyst Biosciences (CBIO) & Revance Therapeutics (RVNC)

Catalyst Biosciences (NASDAQ: CBIO) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Earnings & Valuation

This table compares Catalyst Biosciences and Revance Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Catalyst Biosciences $1.02 million 126.07 -$21.56 million ($7.45) -1.45
Revance Therapeutics $260,000.00 4,349.94 -$120.58 million ($4.01) -7.67

Catalyst Biosciences has higher revenue and earnings than Revance Therapeutics. Revance Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Catalyst Biosciences and Revance Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Catalyst Biosciences -2,983.40% -39.27% -34.64%
Revance Therapeutics -33,807.37% -63.68% -54.86%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Catalyst Biosciences and Revance Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catalyst Biosciences 0 0 2 0 3.00
Revance Therapeutics 0 1 10 0 2.91

Catalyst Biosciences presently has a consensus price target of $39.50, suggesting a potential upside of 266.76%. Revance Therapeutics has a consensus price target of $47.20, suggesting a potential upside of 53.50%. Given Catalyst Biosciences’ stronger consensus rating and higher possible upside, equities analysts clearly believe Catalyst Biosciences is more favorable than Revance Therapeutics.

Institutional and Insider Ownership

76.8% of Catalyst Biosciences shares are held by institutional investors. Comparatively, 93.0% of Revance Therapeutics shares are held by institutional investors. 3.1% of Catalyst Biosciences shares are held by company insiders. Comparatively, 5.1% of Revance Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Catalyst Biosciences has a beta of 2.39, suggesting that its share price is 139% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.

Summary

Catalyst Biosciences beats Revance Therapeutics on 9 of the 14 factors compared between the two stocks.

About Catalyst Biosciences

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing CB 2679d/ISU304, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis for development and manufacturing of the Factor IX products through Phase I/II clinical trials. The company has strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases. The company is headquartered in South San Francisco, California.

About Revance Therapeutics

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. Revance Therapeutics, Inc. has a collaboration agreement with Mylan N.V. (MYL) for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply